Description
CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research[1].–Applications-Cancer-programmed cell death-Formula-C71H94FN11O22-Citation–References-[1]Weijia Tang, et al. Method for treating her2-positive solid tumor. Patent WO2023198079A1. -CASNumber-2879247-31-9-MolecularWeight-1472.56-Compound Purity–SMILES-O=C(C=CC1=O)N1CC(N[C@@H](CCNC(CCOCCOCCOCCOCCOCCOCCOCCOC)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC(C=C2)=CC=C2COC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Drug-Linker Conjugates for ADC;Topoisomerase-Isoform-Camptothecins-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage-MCE Product type-ADC Related
